Leading Microbiome CDMO Serving the Expanding Market

Published: January 2024


Given the role of the microbiota in both disease development and pathogenesis, the concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. We analyzed several Microbiome CDMO that offer contract manufacturing services for microbiome manufacturing. In this article, discover insights on top 5 microbiome CDMOs.


There have been several developments in the field of microbiome-based therapeutics, and despite decades of experience in culturing bacteria to produce biologics, the biotech industry is still struggling with manufacturing of live bacterial therapies at scale. The equipment for manufacturing is not yet in place, and industry is plagued by various challenges. Key concerns for contemporary innovators include extended development times, stringent temperature control requirements, complex designs for various aerobic / anaerobic loads, and unstable quality characteristics of the final product. Therefore, outsourcing the manufacturing of microbiome therapeutics to CMOs or CDMOs turns out to be a favorable option for microbiome drug developers to overcome existing manufacturing challenges.

Roots Analysis has conducted an exhaustive study on Microbiome Manufacturing Market featuring the current market landscape of microbiome CDMOs as well in-house players and future opportunity, over the forecast period 2023-2035.

Table of Contents

Below, we have listed (in alphabetical order), the top 5 microbiome CDMO, based on their service portfolio / capabilities.

Company    Year of Establishment                     Headquarters     Employee Count          
BacThera 2019 BacThera-headquarter 51-200
Biose Industrie 1951 Biose-Industrie-headquarter 51-200
BJP Laboratories 1992 BJP-Laboratories-headquarter 51-200
Cerbios-Pharma 1976 Cerbios-Pharma-headquarter 51-200
WACKER 1914 WACKER-headquarter 10,001+


Interested in exploring all 20+ live biotherapeutic products and microbiome CDMOs?

Discover the Details on 5 Microbiome CDMO Leading the Pace in Microbiome Manufacturing

This article highlights the top 5 players to watch out for in this industry. These companies were chosen based on their prominence in the industry and have the capability to offer contract manufacturing services for microbiome-based live biotherapeutics at both clinical and commercial scales. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

BacThera, Microbiome CDMO Supporting the Launch of Recently Approved Microbiome Therapy in the US

BacThera - Microbiome Manufacturing Organizaiton


BacThera is a contract development and manufacturing organization that claims to offer wide range of services, including technical processes, formulation and analytical development from clinical to commercial scale.  In addition, the firm offers a range of technologies to overcome manufacturing challenges in the LBP industry and delivers viable products to the desired target site.  Further, the firm has been accredited with various regulatory certifications, including DKMA and Swissmedic.

BacThera is the official manufacturing partner for Seres Therapeutics and Nestle Health Science’s recently approved SER-109, brand named VOWST.

The following table presents the details on the microbiome manufacturing related services offered by BacThera:

Parameter Description               
Number of Facility 2
Location of Manufacturing Facility
  • Basel, Switzerland
  • Horsholm, Denmark
Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
Type of Formulation
  • Solids
Type of Primary Packaging Used
  • Blister Packs
Type of Microbe Manufactured
  • Aerobic
  • Anaerobic


Recent Initiatives Undertaken by BacThera:

  • In October 2023, the company opened a new microbiome center of excellence in Visp, Switzerland to support the manufacturing of life-saving microbiome-based therapies, such as SER-109.1 
  • In April 2023, BacThera joined the Microbiome Therapeutic Innovations Group (MTIG). BacThera will be the first CDMO to join the coalition for advancing the research on novel microbiome therapeutic drugs by providing services for live biotherapeutics products (LBP) and process chain.

Biose Industrie’s Live Biotherapeutic Product-Focused Manufacturing Service Offerings Range from Early Discovery to CMC Development

Biose Industrie - Microbiome Manufacturing Organizaion


Biose Industrie is a French CDMO that claims to offer various services, ranging from discovery to registration, for live biotherapeutic products at clinical and commercial scales. As per the firm’s website, it has the required capabilities to carry out operations under biosafety level-1 and level-2 conditions. Further, the firm has been accredited with various regulatory certifications, including the GMP.

The following table presents the details on the microbiome manufacturing related services offered by Biose Industrie:

Parameter Description               
Number of Facility 1
Location of Manufacturing Facility  
  • Auvergne-Rhone-Alpes, France
Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
Type of Formulation
  • Solids
  • Liquids
Type of Primary Packaging Used
  • Blister Packs
  • Glass / Plastic Bottles
  • Sachets / Pouches
  • Vials
Type of Microbe Manufactured
  • Aerobic
  • Anaerobic


Recent Initiatives Undertaken by Biose Industrie:

  • In June 2023, the company inked a technology utilization agreement with SBT Instruments in order to implement the latter company’s technology within the former company’s manufacturing process, with an aim to shorten the drug development timelines from clinical trials to market.2
  • In March 2023, the company announced the establishment of a new facility in Massachusetts, US in order to strengthen its market position.
  • In February 2023, the company successfully raised EUR 80 million from L-GAM and the French State to boost the workforce and manufacturing capabilities of live biotherapeutic products.

With a Focus on Development and Manufacturing of Probiotics, BJP Laboratories Aims to Overcome the Concerns Related to Stability and Delivery of Microbiome Therapeutics

BJP Laboratories - Microbiome Manufacturing Organization


BJP Laboratories is an Australian company that claims to be engaged in the manufacturing of probiotic products, medicines, food and dietary supplements. Additionally, the company offers various services, including analytical and manufacturing services at preclinical, clinical and commercial scales of operations. As per the firm’s website, it has two facilities based in Australia, which are dedicated to carry out the GMP manufacturing of probiotic products and dietary supplements.

The following table presents the details on the microbiome manufacturing related services offered by BJP Laboratories:

Parameter Description               
Number of Facility 2
Location of Manufacturing Facility  
  • Queensland, Australia (2)
Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
Type of Formulation
  • Solids
  • Liquids
Type of Primary Packaging Used
  • Glass / Plastic Bottles
  • Sachets / Pouches
Type of Microbe Manufactured
  • Anaerobic


Cerbios-Pharma, A Switzerland Based Microbiome CDMO, Offers a Broad Spectrum of Services for Pharmaceutical Probiotics

Cerbios-Pharma - Microbiome Manufacturing Organization

Cerbios-Pharma is a Swiss CDMO, which was established in 1976.  As per the firm’s website, it offers services for high-potency active pharmaceutical ingredients (HPAPIs), antibody drug conjugates (ADCs), live biotherapeutics, proteins, and antibodies. Further, the company claims to own a center of excellence facility dedicated for the development of APIs (including small molecules and biologics) in Lugano, Switzerland, and a manufacturing facility for reduced folates in Neuchâtel, Switzerland

The following table presents the details on the microbiome manufacturing related services offered by Cerbios-Pharma:

Parameter Description               
Number of Facility 1
Location of Manufacturing Facility  
  • Lugano, Switzerland
Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
Type of Formulation
  • Solids
  • Liquids
Type of Primary Packaging Used
  • Glass / Plastic Bottles
Type of Microbe Manufactured
  • Anaerobic


Recent Initiatives Undertaken by Cerbios-Pharma:

  • In May 2023, the firm received Swissmedic approval for its production plant based in Lugano, Switzerland for the manufacturing of clinical and commercial highly potent APIs.

With its Collaborative Industrial and Technological-based Expertise, WACKER is Committed to Provide Cost-Effective and Efficient Manufacturing Solutions to Advance Healthcare Products

WACKER - Microbiome Manufacturing Organization

WACKER is a German CDMO that claims to offer a diverse range of services related to research and development, as well as manufacturing.  The company employs a unique business approach that provides integrated services, including contract research, development, and manufacturing services for chemical drugs, discovery services for biologics, preclinical testing, clinical research, and contract testing, development, and manufacturing services for therapeutic proteins, vaccines, live biotherapeutic products, plasmid DNA and mRNA. Further, the firm claims these solutions to be cost-effective and efficient, allowing the customers to improve productivity in advancing healthcare products.  As per the firm’s website, it offers a wide portfolio of over 3,200 products.

The following table presents the details on the microbiome manufacturing related services offered by WACKER:

Parameter Description               
Number of Facility 4
Location of Manufacturing Facility  
  • Amsterdam, Netherlands
  • California, US
  • Halle, Germany
  • Jena, Germany
Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
Type of Formulation
  • Liquids
Type of Primary Packaging Used
  • Vials
Type of Microbe Manufactured
  • Aerobic
  • Anaerobic


Recent Initiatives Undertaken by WACKER:

  • In June 2023, the company participated in the 8th Microbiome Movement: Drug Development Summit, held in Massachusetts, US.

What About the Other Microbiome CDMOs?

The above presentation features 5 microbiome CDMO selected from a pool of over 20 companies that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com

About Author

Jasmeet Bhalla

With an experience of over 4 years with Roots Analysis, Jasmeet is adept at generating useful insights from unstructured / structured datasets. As a senior analyst at Roots Analysis, she has assisted several clients across multiple industry verticals within the healthcare industry. These verticals include contract services, devices / technologies, and drugs / disease indications. Since the findings of the research are aimed at supporting the clients to make thoughtful decisions for their business, she has hands-on experience on competitive landscape assessment, benchmarking, market sizing and forecasting, as well as several quantitative / qualitative / strategic frameworks.

Sources:

  1. “Bacthera’s Visp plant aims to revolutionize microbiome-based treatments https://ggba.swiss/en/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments/
  2. “Biose Industrie & SBT Instruments enter collaboration to revolutionize bacterial enumeration within the live biotherapeutic market”
  3. “HPAPI and ADC payload manufacturing capacity expansion” https://cerbios.swiss/hpapi-and-adc-payload-manufacturing-capacity-expansion/

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry